SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
11 references·0 citing·48 second hop
Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review (2022)Economic and Humanistic Burden of Triple-…The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review (2021)The Out-of-Pocket Cost Burden…Adjusting for Inflation and Currency Changes Within Health Economic Studies (2019)Adjusting for Inflation and C…The economic burden of metastatic breast cancer: a U.S. managed care perspective (2012)The economic burden of metast…The economic burden of metastatic breast cancer: A systematic review of literature from developed countries (2011)The economic burden of metast…The Cochrane Collaboration's tool for assessing risk of bias in randomised trials (2011)The Cochrane Collaboration's …Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research (2011)Economic Burden of Cancer in …Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (2009)Preferred reporting items for…Evaluation of Trends in the Cost of Initial Cancer Treatment (2008)Evaluation of Trends in the C…Assessing the economic burden of breast cancer in a US managed care population (2007)Assessing the economic burden…Breast Cancer Management (2003)Breast Cancer ManagementEstimates of the Lifetime Direct Costs of Treatment for Metastatic Breast Cancer (2000)Estimates of the Lifetime Dir…Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at Diagnosis (1995)Stage, Age, Comorbidity, and Direct Costs of Colon, Prostate, and Breast Cancer Care (1995)Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data (2002)The costs of breast cancer prior to and following diagnosis (2010)Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality (2011)INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES (2012)Estimates of the lifetime costs of breast cancer treatment in Canada (2000)Costs and Health Effects of Breast Cancer Interventions in Epidemiologically Different Regions of Africa, North America, and Asia (2006)Economic burden associated with breast cancer recurrence (2006)The Costs of Treating Breast Cancer in the US (2009)Assessing the quality of controlled clinical trials (2001)Assessing Risk of Bias in Included Studies (2008)Cochrane Handbook for Systematic Reviews of Interventions (2008)ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions (2016)RoB 2: a revised tool for assessing risk of bias in randomised trials (2019)Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal (2024)Health Care Financing Review (1980)The Distinction Between Cost and Charges (1982)National Estimates of Out-of-Pocket Health Care Expenditure Burdens Among Nonelderly Adults With Cancer: 2001 to 2008 (2011)Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service. (2016)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Trastuzumab in early stage breast cancer: A cost-effectiveness analysis for Belgium (2008)Indirect costs associated with metastatic breast cancer (2013)Cost-Effectiveness in Health and Medicine (1996)Medical Bankruptcy in the United States, 2007: Results of a National Study (2009)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer (2016)Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer (2018)Global and regional estimates of orphans attributed to maternal cancer mortality in 2020 (2022)Designing and Conducting Cost-effectiveness Analyses in Medicine and Health Care (2002)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Breast cancer surgery and diagnosis-related groups (DRGs): Patient classification and hospital reimbursement in 11 European countries (2012)The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies (2007)The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration (2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration (2009)PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation (2018)The PRISMA 2020 statement: an updated guideline for reporting systematic reviews (2021)A Mathematical Theory of Saving (1928)Asset Prices in an Exchange Economy (1978)Making choices in health: who guide to cost-effectiveness analysis (2004)Stark choices: exploring health sector costs of policy responses to COVID-19 in low-income and middle-income countries (2021)Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review (2023)An overview of the perspectives used in health economic evaluations (2024)Estimating the mean and variance from the median, range, and the size of a sample (2005)Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (2009)The Economic Burden of Cancer in Canada from a Societal Perspective (2022)The economic impact of cancer diagnosis to individuals and their families: a systematic review (2022)ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer (2024)
this work references cited by second hop

References

  • 2009Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement84,364 cited
  • 2011The Cochrane Collaboration's tool for assessing risk of bias in randomised trials33,820 cited
  • 2011Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research504 cited
  • 2008Evaluation of Trends in the Cost of Initial Cancer Treatment388 cited
  • 2019Adjusting for Inflation and Currency Changes Within Health Economic Studies342 cited
  • 2021The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review219 cited
  • 2003Breast Cancer Management146 cited
  • 2007Assessing the economic burden of breast cancer in a US managed care population94 cited
  • 2011The economic burden of metastatic breast cancer: A systematic review of literature from developed countries64 cited
  • 2000Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast Cancer60 cited
  • 2012The economic burden of metastatic breast cancer: a U.S. managed care perspective57 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work